Profund Advisors LLC Sells 8,642 Shares of Elanco Animal Health (NYSE:ELAN)

Profund Advisors LLC cut its holdings in Elanco Animal Health (NYSE:ELAN) by 23.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 28,091 shares of the company’s stock after selling 8,642 shares during the period. Profund Advisors LLC’s holdings in Elanco Animal Health were worth $949,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new position in Elanco Animal Health in the 2nd quarter worth approximately $32,000. Capital Investment Advisory Services LLC boosted its holdings in Elanco Animal Health by 1,501.4% in the 2nd quarter. Capital Investment Advisory Services LLC now owns 1,121 shares of the company’s stock worth $36,000 after buying an additional 1,051 shares during the period. Valeo Financial Advisors LLC boosted its holdings in Elanco Animal Health by 376.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 1,430 shares of the company’s stock worth $48,000 after buying an additional 1,130 shares during the period. Citizens Financial Group Inc RI bought a new position in Elanco Animal Health in the 1st quarter valued at $48,000. Finally, Barrett Asset Management LLC bought a new position in Elanco Animal Health in the 1st quarter valued at $48,000.

Several research analysts have commented on the stock. Bank of America downgraded shares of Elanco Animal Health from a “buy” rating to a “neutral” rating and set a $30.00 price target for the company. in a report on Monday, August 26th. Guggenheim assumed coverage on shares of Elanco Animal Health in a report on Wednesday, May 22nd. They issued a “neutral” rating for the company. UBS Group raised shares of Elanco Animal Health from a “sell” rating to a “neutral” rating and cut their price target for the company from $31.00 to $30.00 in a report on Thursday, August 15th. Zacks Investment Research downgraded shares of Elanco Animal Health from a “hold” rating to a “sell” rating in a report on Friday, September 6th. Finally, Goldman Sachs Group assumed coverage on shares of Elanco Animal Health in a report on Monday, September 9th. They issued a “positive” rating for the company. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $33.64.

In related news, CEO Jeffrey N. Simmons acquired 75,750 shares of the stock in a transaction dated Wednesday, September 4th. The shares were purchased at an average price of $26.55 per share, for a total transaction of $2,011,162.50. Following the transaction, the chief executive officer now owns 470,006 shares in the company, valued at approximately $12,478,659.30. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Deborah Turner Kochevar bought 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The stock was acquired at an average price of $27.95 per share, for a total transaction of $27,950.00. In the last 90 days, insiders have bought 112,780 shares of company stock worth $3,003,162. Corporate insiders own 0.04% of the company’s stock.

Shares of Elanco Animal Health stock traded down $0.35 on Monday, hitting $28.33. 40,553 shares of the company traded hands, compared to its average volume of 4,993,809. The firm’s 50-day simple moving average is $29.25 and its 200 day simple moving average is $31.55. The company has a current ratio of 3.07, a quick ratio of 1.71 and a debt-to-equity ratio of 0.45. The company has a market cap of $10.38 billion and a P/E ratio of 24.03. Elanco Animal Health has a 12-month low of $25.51 and a 12-month high of $37.61.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported $0.28 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.02. The firm had revenue of $781.60 million for the quarter, compared to analysts’ expectations of $781.49 million. Elanco Animal Health had a net margin of 4.69% and a return on equity of 7.83%. The company’s revenue for the quarter was up 1.5% on a year-over-year basis. Analysts predict that Elanco Animal Health will post 1.08 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

See Also: Why is the ex-dividend date different from the record date?

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.